2023-09-17 12:05:17
This decision follows the previous approval of the updated version of the vaccin Pfizer-BioNTech. Although the World Health Organization (WHO) removed the status of global health emergency from Covid-19 since May, the virus has continued to circulate and new strains are emerging. The XBB.1.5 subvariant has recently affected many French people during summer.
In order to better combat this sub-variant in preparation for winter, European Commission gives green light to updated Moderna vaccine, thus joining the decision taken in September for the Pfizer-BioNTech vaccine. In June, the European Medicines Agency (EMA) recommended updating vaccines to target the XBB strain of the virus, which has become predominant in Europe and other parts of the world. Moderna’s updated vaccine, targeting Omicron’s XBB.1.5 sub-variant, has been authorized for use in adults and children over 5 years old. Only one injection is necessary, regardless of previous vaccinations. The Moderna and Pfizer-BioNTech vaccines generally provide increased protection once morest other variants currently circulating, and both recently received approval from the EMA, the European regulator (source 1).
The Commission has authorized the placing on the market of these updated vaccines in under an accelerated procedure, allowing Member States to prepare for their autumn and winter vaccination campaigns. At the same time, American health authorities have also given authorization for updates to the Moderna and Pfizer-BioNTech vaccines, while the number of hospitalizations linked to Covid-19 is increasing in the United States.
1694957282
#green #light #updated #Moderna #vaccine #targeting #Covid19 #subvariant #XBB.1.5
